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D E f I N I t I O N
Several definitions of diastolic heart failure have been proposed. One definition 
is, “a condition resulting from an increased resistance to filling of one or both ventri-
cles leading to symptoms of congestion due to an inappropriate upward shift of the 
diastolic pressure –volume relation (that is during the terminal phase of the cardiac 
cycle)”. Another proposed definition is that diastolic heart failure is a condition in 
which the “ventricular chamber is unable to accept an adequate volume of blood 
during diastole at normal diastolic pressures and at volumes sufficient to maintain an 
appropriate stroke volume”. These definitions describe pathophysiology and functional 
abnormalities but cannot be applied in clinical practice.
The widely used clinical definition of diastolic heart failure is, “a clinical condition 
characterized by the presence of signs and symptoms of heart failure and preserved 
left ventricular ejection fraction”. Based on this definition, diastolic heart failure is 
also termed “heart failure with preserved ejection fraction”.
r E m O D E L I N G
In diastolic heart failure, left ventricular cavity size is normal or decreased. End 
diastolic volume remains normal or even decreased. End systolic volume is usually 
smaller and therefore ejection fraction is normal. Left ventricular dilatation does not 
occur without ischemic myocyte necrosis. Left ventricular wall thickness and mass is 
increased. The cavity/mass ratio is decreased.
Left ventricular hypertrophy is uniformly present. The myocyte diameter is in-
creased but its length remains normal, thus the myocyte length/width ratio is decreased. 
The sarcomeres are replicated in parallel. There are also considerable changes in the 
matrix. The collagen volume is substantially increased. There is increased width and 
continuity of fibrillar collagen. Collagen-cross links are increased. In general, the 
matrix metalloproteinases levels are decreased and their endogenous tissue inhibi-
tors are increased in diastolic heart failure. The titin isoforms N2BA/N2B ratio is 
increased in diastolic heart failure.
f U N c t I O N A L  c H A N G E s
Increased left ventricular passive stiffness and impaired left ventricular relaxa-
tion is the principal functional abnormality in diastolic heart failure. The diastolic 
pressure-volume relation shifts upward and to the left which is associated with a 
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disproportionately greater increase in diastolic pressure for 
any increase in volume.
In advanced diastolic heart failure, left ventricular end 
diastolic pressure may exceed 20-25 mmHg which may cause 
pulmonary congestion and dyspnea. There is also a passive 
increase in pulmonary venous pressure which is associated 
with postcapillary pulmonary hypertension. Chronic increase 
in pulmonary venous pressure frequently causes mixed pul-
monary hypertension. Because of pulmonary hypertension, 
right heart failure ensues with its signs and symptoms such as 
peripheral edema, hepatomegaly and even secondary tricuspid 
regurgitation. If there is also marked restriction of ventricular 
filling, stroke volume and cardiac output is decreased without 
any change in contractile function and ejection fraction. Thus, 
in advanced diastolic heart failure, the hemodynamic profile 
may be similar to that of severe systolic heart failure. The 
structural and functional changes in diastolic heart failure 
are summarized in Table 1.
D O E s  t H E  L E f t  v E N t r I c L E  D I L A t E  I N 
D I A s t O L I c  H E A r t  f A I L U r E ?
There are controversies about changes in left ventricular 
function and morphology in diastolic heart failure. Some 
authorities have hypothesized that the left ventricle can dilate 
significantly along with reduced ejection fraction. However, 
recent studies have demonstrated that during an average of 
64 months of follow-up, in patients with diastolic heart failure 
without coronary artery disease, left ventricular volumes and 
ejection fraction remain unchanged. The left ventricular end 
diastolic pressures and stiffness increase, suggesting that left 
ventricular diastolic function worsens in these patients.
t H E r A P E U t I c  O P t I O N s
Unlike systolic heart failure, there has been very little 
progress in the management of diastolic heart failure. For 
the relief of congestive symptoms, diuretics and nitrates are 
necessary. However, excessive diuretic or nitrate therapy may 
be associated with inappropriate reduction of preload and 
cardiac output and hypotension.
To maintain appropriate time for ventricular filling, the 
heart rate needs to be controlled either pharmacologically or 
by pacemaker therapy. It is desirable to maintain sinus rhythm 
in diastolic heart failure to maintain adequate stroke volume 
and cardiac output.
To decrease mortality or morbidity, very few pharmaco-
logic events have been evaluated. The “CHARM Preserved” 
trial has reported that the angiotensin receptor blocking 
agent candesartan may decrease hospital admission rates. It 
should be emphasized that non-pharmacologic therapy, such 
as chronic resynchronization with or without defibrillator 
therapy, has not been shown to provide any benefit.
It is apparent that further research and investigations are 
required to determine potential beneficial therapies for treat-
ment of diastolic heart failure. There is, however, extensive 
research being undertaken to discover potential new and ef-
fective therapeutic agents for the treatment of diastolic heart 
failure (Table 2).
tAbLE 1. The structural and functional changes in diastolic 
heart failure.
Parameters Diastolic heart failure
LV end diastolic volume Normal or decreased
LV end systolic volume Normal or decreased
Ejection fraction Normal
LV mass Increased
LV wall thickness Increased
LV end systolic stress Normal
LV end diastolic stress Increased
Mechanical dyssynchrony May be present
LV shape and geometry Usually unchanged
Myocyte hypertrophy Present
Myocardial fibrosis Present
Calcium regulation Abnormal
MMPs/TIMPs Decreased
Collagen cross links Increased
Titin isoforms N2BA/N2B Decreased
tAbLE 2. Potential new therapies for diastolic heart fail-
ure.
to decrease myocardial fibrosis:
  Aldosterone antagonists
  Angiotensin inhibition
  Chymase antagonists
  TGF –beta
to improve relaxation
  Phospholamban inhibitors
  D- ribose
Modulation of collagen cross-links
Modulation of Titin isoforms
Modulation of MMPs/TIMPs
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c O N c L U s I O N s
The pathophysiology, remodeling and functional changes 
in diastolic heart failure are characterized by the lack of 
ventricular dilatation, normal ejection fraction and increased 
fibrosis and left ventricular stiffness. The hemodynamic pro-
file is similar to that of systolic heart failure. The therapeutic 
modalities available are limited. Further and continued re-
search is necessary to discover new and effective treatment 
of this syndrome, which is associated with poor prognosis 
particularly in advanced diastolic heart failure.
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